HOME >> MEDICINE >> NEWS
Initial chemotherapy treatment reduces relapses in MS patients

DENVER, CO Mitoxantrone, a chemical routinely used to fight breast cancer, leukemia and malignant lymphoma, has found a new disease to battle: Multiple Sclerosis. Used in an initial intensive course of chemotherapy (induction therapy), mitoxantrone dramatically decreases disease activity in MS patients for at least four years, according to a study presented at the Annual Meeting of the American Academy of Neurology.

Induction therapy, frequently used against cancers, is designed to wipe out abnormal cells and allow for the regrowth of normal cells. Mitoxantrone for the treatment of MS has recently been approved by the U.S. Food and Drug Administration. It has been used to treat MS in France for more than a decade. Researchers from CHU Pontchaillou of Rennes, France, have demonstrated that mitoxantrone induction therapy for relapsing-remitting MS patients has produced dramatic results in disease activity.

Over the past ten years, 100 worsening relapsing-remitting MS patients were given initial mitoxantrone induction therapy for six months, with mitoxantrone combined with methylprednisolone administered intravenously on a monthly schedule. The annual relapse rate decreased significantly from 3.20 during the 12 months preceding mitoxantrone onset to 0.30 during the first year following induction onset, corresponding to a reduction of nearly 90 percent that was maintained for more than five years. The percentage of relapse-free patients was 76 percent at one year of follow-up, and was maintained at 64 percent, 45 percent, and 43 percent at years two, three and four, respectively, with a median time to the first relapse of 2.8 years.

The clinical benefit and reduction of disease activity supports our belief that mitoxantrone, as administered in this study, may be an effective induction treatment before initiating other long-term disease modifying therapies for worsening relapsing-remitting MS patients, commented study author Emmanuelle Le Pa
'"/>

Contact: Cheryl Alementi
calementi@aan.com
651-695-2737
American Academy of Neurology
17-Apr-2002


Page: 1 2

Related medicine news :

1. Initial findings of first comprehensive study into ageing process published
2. Initial Avon/NCI breast cancer research grants awarded in Progress for Patients awards program
3. Initially recommended drug dosages often too high, study finds
4. Initial clinical study shows safety and bioactivity of cancer vaccine
5. Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer
6. Breakthrough in medical research: New chemotherapy gives hope to brain tumour patients
7. MRI better than current standard in assessing neoadjuvant chemotherapy for breast cancer
8. Older women can benefit from chemotherapy to treat breast cancer
9. Resistance to chemotherapy
10. New treatment rivals chemotherapy for lymphoma, U-M study finds
11. Adding radiation therapy to chemotherapy improves survival in patients with high-risk breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Initial chemotherapy treatment reduces relapses patients

(Date:3/27/2015)... GrassrootsHealth, an international nonprofit public health ... NOW! vitamin D demonstration project April 7 in the ... (MUSC), and will soon follow with a second phase ... to a minimum of 500 pregnant women at 17 ... service areas. The project will include patient and health ...
(Date:3/27/2015)... Operatic contenders and their avid audience ... 17th. The universally acclaimed baritone Sherrill Milnes will be ... Idol at The Merion in Evanston. The event is ... aspiring opera singers from around the country. “This is ... finest young talent in the country,” said Margaret Gergen, ...
(Date:3/27/2015)... March 27, 2015 Approximately 300 ... Healthy Kids Coalition Lobby Day to lobby for ... Improvement Program (SHIP). Everlast Climbing was especially ... Bill SF343/HF498 which would strengthen physical education programs ... assessments and other measures to strengthen physical education ...
(Date:3/27/2015)... 2015 Airy Jeanine is a rising ... music video for her debut song “Mama’s Girl”, launched ... and abstract styling effects, the thematic video for the ... Vimeo, and assorted outlets. It will be integral in ... expanding full-scale marketing strategy. The video promotion campaign spearheaded ...
(Date:3/27/2015)... 2015 April 2015 is the 150th anniversary ... To honor America’s bloodiest war and the amazing President that ... A Tribute to the Civil War and Abraham Lincoln. This ... 2015, at the Jane Pickens Theater in Newport, RI. ... will serve as the master of ceremonies. Dr. Fred Zilian, ...
Breaking Medicine News(10 mins):Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 2Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 3Health News:GrassrootsHealth Moves Vitamin D into Practice with Pregnant Women 4Health News:Opera Idol Competition At The Merion In Evanston 2Health News:Everlast Climbing Advocates to Strengthen Physical Education in Minnesota Schools 2Health News:Airy Jeanine Releases ‘’Mama’s Girl” Official Music Video 2Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 2Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 3Health News:Relive the Civil War, the Presidency and Shocking Assassination of Abraham Lincoln through Lincoln’s Own Words and the Music of a 46-Piece Orchestra 4
(Date:3/27/2015)... According to a new market ... Advanced, Ultrasound), Ablation Catheter (Cryoablation, RF, Microwave), Lab Devices ... WPW) - Global Forecasts to 2019 ", published by MarketsandMarkets, ... ~$4.73 Billion by 2019 with a CAGR of around ... Browse   90   ma rket ...
(Date:3/27/2015)... , March 27, 2015 The International Myeloma ... myeloma patients while working toward prevention and a cure ... for introducing a federal resolution (H. Res. 174) that ... as "National Multiple Myeloma Awareness Month." Currently ... worldwide, and more than 110,000 new cases are diagnosed ...
(Date:3/27/2015)... , March 27, 2015  RXi ... privately-held MirImmune LLC, today announced that they ... to RXi,s novel and proprietary sd-rxRNA® technology ... immunotherapies. The collaboration has the potential to ... friendly cancer treatments that could be a ...
Breaking Medicine Technology:Electrophysiology (EP) Market Worth $4.73 Billion by 2019 2Electrophysiology (EP) Market Worth $4.73 Billion by 2019 3Electrophysiology (EP) Market Worth $4.73 Billion by 2019 4The International Myeloma Foundation (IMF) Secures the Introduction of a Federal Resolution Recognizing March 2015 as "National Multiple Myeloma Awareness Month" 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 2RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 3RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 4RXi Pharmaceuticals and MirImmune LLC Enter into an Exclusive Licensing Agreement for RXi's Self-Delivering RNAi (sd-rxRNA) Technology to Develop Cell-based Immunotherapies to Treat Cancer 5
Cached News: